Allogene Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Allogene Therapeutics, Inc. (ALLO) reported Increase Decrease In Operating Lease Liability of -$4.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-12
- Allogene Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$2.04M.
- Allogene Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$2.20M.
- Allogene Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.89M.
- Allogene Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.85M.
- Allogene Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$7.50M.
- Allogene Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$6.31M.
- Allogene Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$6.00M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$4.25M 10-Q · filed 2026-08-12 | -$6.13M derived: sum of 3 quarters · filed 2026-08-12 | -$7.99M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$2.20M 10-Q · filed 2026-05-13 | -$4.09M derived: sum of 2 quarters · filed 2026-05-13 | -$5.95M derived: sum of 3 quarters · filed 2026-05-13 | -$7.87M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$3.74M derived: sum of 2 quarters · filed 2026-03-12 | -$5.67M derived: sum of 3 quarters · filed 2026-08-12 | -$7.50M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.78M derived: sum of 2 quarters · filed 2026-08-12 | -$5.61M 10-Q · filed 2025-11-06 | -$7.39M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$3.76M 10-Q · filed 2026-08-12 | -$5.54M derived: sum of 3 quarters · filed 2026-08-12 | -$7.22M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$1.83M 10-Q · filed 2026-05-13 | -$3.61M derived: sum of 2 quarters · filed 2026-05-13 | -$5.29M derived: sum of 3 quarters · filed 2026-05-13 | -$6.93M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$3.46M derived: sum of 2 quarters · filed 2026-03-12 | -$5.10M derived: sum of 3 quarters · filed 2026-03-12 | -$6.31M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.32M derived: sum of 2 quarters · filed 2025-11-06 | -$4.53M 10-Q · filed 2025-11-06 | -$6.09M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$2.85M 10-Q · filed 2025-08-13 | -$4.40M derived: sum of 3 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$1.21M 10-Q · filed 2025-05-13 | -$2.77M derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$6.00M 10-K · filed 2025-03-13 | ||
| 2023-09-30 | -$4.45M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |